Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 12, 2014, Pages 4759-4769

  Li, Xueren ^a   Peng, Shouchun ^a   Wei, Luqing ^a   Li, Zhenhua ^b  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Diopathic pulmonary fibrosis; Prognosis; Respiratory assessment parameters; Survival analysis

Indexed keywords

HEMOGLOBIN;

ADULT; ARTERIAL GAS; ARTICLE; BLOOD GAS ANALYSIS; CARBON MONOXIDE BLOOD LEVEL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; OXYGEN TENSION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TOTAL LUNG CAPACITY;

EID: 84921502069     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Nicholson AG, Colby TV, du Bois RM, Hansell DM and Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-2217.
3. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM and Coultas DB. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998; 53: 469-476.
4. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR and Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
5. Hubbard R, Johnston I and Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396-400.
6. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R and Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-1072.
7. King TE Jr, Tooze JA, Schwarz MI, Brown KR and Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
8. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ and Greater Manchester Pulmonary Fibrosis C. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108.
9. Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, Horrocks AW, Wilson M, McCullough C, Prescott M, Egan JJ; Greater Manchester Pulmonary Fibrosis Consortium. Pulmonary (99m) Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001; 56: 916-923a.
10. Hanson D, Winterbauer RH, Kirtland SH and Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305-310.
11. Leslie KO, Cool CD, Sporn TA, Curran-Everett D, Steele MP, Brown KK, Wahidi MM and Schwartz DA. Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012; 136: 1366-1376.
12. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr and Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
13. Soares Pires F, Caetano Mota P, Melo N, Costa D, Jesus JM, Cunha R, Guimaraes S, Souto-Moura C and Morais A. Idiopathic pulmonary fibrosis--clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol 2013; 19: 19-27.
14. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI and Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
15. Sun WX, Jin D, Li Y and Wang RT. Increased arterial stiffness in stable and severe asthma. Respir Med 2014; 108: 57-62.
16. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
17. Schwartz DA, Van Fossen DS, Davis CS, Helmers RA, Dayton CS, Burmeister LF and Hunninghake GW. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 444-449.
18. Erbes R, Schaberg T and Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997; 111: 51-57.
19. King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W and Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164: 1025-1032.
20. McCormack FX, King TE Jr, Bucher BL, Nielsen L and Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152: 751-759.
21. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144: 1202-1218.
22. Tukiainen P, Taskinen E, Holsti P, Korhola O and Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-355.
23. Rudd RM, Haslam PL and Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1-8.
24. Jezek V, Fucik J, Michaljanic A and Jezkova L. The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopathol Respir 1980; 16: 711-720.
25. Hubbard R, Venn A, Smith C, Cooper M, Johnston I and Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998; 157: 743-747.
26. Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR, Caron GM and DeRemee RA. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158: 220-225.
27. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE and Winterbauer RH. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
28. Raghu G, Johnson WC, Lockhart D and Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069.
29. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198.